Krystal Biotech (KRYS) Revenue (2023 - 2026)

Krystal Biotech has reported Revenue for 4 years, with the latest figure at $119.2 million in Q2 2026.

• Revenue for Q2 2026 came in at $119.2 million, up 24.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $440.5 million (up 22.64% YoY), and the FY2025 annual result was $389.1 million, up 33.94% from the prior year.
• Revenue improved to $119.2 million in Q2 2026, from $116.4 million in the prior quarter.
• Over five years, Revenue peaked at $119.2 million in Q2 2026 and troughed at $8.6 million in Q3 2023.
• A 4-year average of $80.5 million and a median of $89.7 million in 2024 frame the typical range for Revenue.
• The widest annual swing landed in 2024, when Revenue soared 879.91%; it then rose 16.65% in 2025.
• A 4-year view of Revenue shows it stood at $42.1 million in 2023, then jumped by 116.2% to $91.1 million in 2024, then increased by 17.55% to $107.1 million in 2025, then advanced by 11.31% to $119.2 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $119.2 million in Q2 2026, $116.4 million in Q1 2026, and $107.1 million in Q4 2025.